The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Rapcabtagene autoleucel for patients with first-line high-risk LBCL: Phase II interim results
In this video, Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses a Phase II trial evaluating rapcabtagene autoleucel (NCT03960840) in patients with first-line high-risk large B-cell lymphoma (LBCL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Rapcabtagene formerly called YTB323, now RAPCAPTAGENE Autolus is an autologous CD19 product being evaluated in B-cell malignancies. It has the very distinct advantage of being a rapidly manufactured product. It’s manufactured using something called the T-Charge platform, which has a manufacturing time of two days. At the ASH 2025 meeting, we’re presenting an update on a trial, and this is the first time we’re presenting data on this cohort of patients treated in first line with large B-cell lymphoma...
Rapcabtagene formerly called YTB323, now RAPCAPTAGENE Autolus is an autologous CD19 product being evaluated in B-cell malignancies. It has the very distinct advantage of being a rapidly manufactured product. It’s manufactured using something called the T-Charge platform, which has a manufacturing time of two days. At the ASH 2025 meeting, we’re presenting an update on a trial, and this is the first time we’re presenting data on this cohort of patients treated in first line with large B-cell lymphoma. These patients have high-risk disease, meaning that they have baseline clinical high-risk, and they have two cycles of chemo with a poor response, and then they enter this single arm study to receive rapcabtagene as a consolidation or as a response improvement for patients that don’t get good benefit from chemotherapy. We’re showing some very promising results and obviously excited for future studies to come with rapcabtagene.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
